# Tharimmune Inc. (THAR)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Price:** $2.30 (-6.12%)

> Tharimmune Inc. is a biotechnology company focused on the development and commercialization of innovative immunotherapies. The company's core purpose is to address unmet medical needs by leveraging cutting-edge research in immunology to create therapies that harness the body's immune system to fight diseases, particularly in the field of oncology and autoimmune disorders. Tharimmune Inc. applies advanced technologies such as monoclonal antibodies and novel biologics in its development pipeline. By operating at the intersection of science and healthcare, the company contributes significantly to the biopharmaceutical industry, driving forward cures and treatments that can transform patient outcomes. As a player in the biotechnology sector, Tharimmune is known for its rigorous research approach and strategic partnerships, which are pivotal in advancing both clinical trials and market approval of its products. The company's commitment to innovation positions it as a vital contributor to the broader healthcare landscape, with potential impacts on patient health and treatment paradigms worldwide. Tharimmune's advancements in immunotherapies underscore its pivotal role in the dynamic and evolving pharmaceuticals market.

Financial data not yet available for this company.

Source: [CompaniesByCap](https://companiesbycap.com/company/THAR)